This project will embark on the current interest in HDAC6 as a therapeutic target, aiming at the development and assessment of new HDAC6 inhibitors as potential novel clinical candidates for anticancer therapy. The research will include activities related to the design, synthesis and biological evaluation of new chemical entities as selective HDAC6 inhibitors on the one hand, and activities related to the assessment of the functional inhibition on tumor cell activities by the new HDAC6 inhibitors on the other hand.